# The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC

> **NCT06965829** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Chest Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Esophageal Cancer Stage III

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Carboplatin and Paclitaxel and Radiation Therapy

## Key facts

- **NCT ID:** NCT06965829
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07-01
- **Primary completion:** 2028-07-01
- **Final completion:** 2028-07-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06965829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06965829, "The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06965829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*